The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder
Abstract
BACKGROUND: Aripiprazole is a dopamine D2 receptor partial agonist with partial agonist activity at serotonin 5HT1A receptors and antagonist activity at 5HT2A receptors. This multicenter trial examined the efficacy, safety, and tolerability of aripiprazole in patients with acute exacerbation of schizophrenia or schizoaffective disorder. METHODS: In this 4-week double-blind study, 404 patients were randomized to 20 mg/d (n = 101) or 30 mg/d (n = 101) of aripiprazole, placebo (n = 103), or 6 mg/d of risperidone (n = 99). Efficacy assessments included Positive and Negative Syndrome Scale (PANSS) scores and Clinical Global Impression scores. Safety and tolerability evaluations included extrapyramidal symptoms and effects on weight, prolactin, and corrected QT (QTc) interval. RESULTS: Aripiprazole (20 and 30 mg/d) and risperidone (6 mg/d) were significantly better than placebo on all efficacy measures. Separation from placebo occurred at week 1 for PANSS total and positive scores with aripiprazole and risperidone and for PANSS negative scores with aripiprazole. There were no significant differences between aripiprazole and placebo in mean change from baseline in the extrapyramidal symptom rating scales. Mean prolactin levels decreased with aripiprazole but significantly increased 5-fold with risperidone. Mean change in QTc interval did not differ significantly from placebo with any active treatment group. Aripiprazole and risperidone groups showed a similar low incidence of clinically significant weight gain. CONCLUSIONS: Aripiprazole is effective, safe, and well tolerated for the positive and negative symptoms in schizophrenia and schizoaffective disorder. It is the first non-D2 receptor antagonist with clear antipsychotic effects and represents a novel treatment development for psychotic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
The Dopamine Hypothesis of Schizophrenia: A Review*
Meltzer, H. Y., & Stahl, S. M. (1976) · Schizophrenia Bulletin · doi:10.1093/schbul/2.1.19 · Cited by 883
Arvanitis, L. A., & Miller, B. G. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00190-x · Cited by 803
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., & Hamilton, S. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 778
The Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 662
Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., Zimbroff, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624
Self-citationAntipsychotic-induced weight gain: a review of the literature.
Allison, D. B., & Casey, D. E. (2001) · PubMed · Cited by 595
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T., & Altar, C. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01532-7 · Cited by 512
Quetiapine in Patients With Schizophrenia: A High- and Low-Dose Double-blind Comparison With Placebo
Small, J. G. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830180067009 · Cited by 478
Marder, S. R., McQuade, R. D., Stock, E., Kaplita, S., Marcus, R., Safferman, A. Z., Saha, A., Ali, M., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00050-1 · Cited by 467
Self-citationOlanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
Beasley, C. M., Sanger, T., Satterlee, W., Tollefson, G., Tran, P., & Hamilton, S. (1996) · Psychopharmacology · doi:10.1007/bf02245617 · Cited by 390
Leysen, J. E., Janssen, P. M. F., Schotte, A., Luyten, W. H. M. L., & Megens, A. A. H. P. (1993) · Psychopharmacology · doi:10.1007/bf02245006 · Cited by 334
Receptor pharmacology of neuroleptics: relation to clinical effects.
Richelson, E. (1999) · PubMed · Cited by 306
Seeman, P., & Tallerico, T. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000336 · Cited by 301
Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors
Millan, M. J. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38982-7 · Cited by 287
Kapur, S., & Seeman, P. M. (2000) · PubMed · Cited by 284
Kikuchi, T., Tottori, K., Uwahodo, Y., Hirose, T., Miwa, T., Oshiro, Y., & Morita, S. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10600-9 · Cited by 276
Borison, R. L., Arvanitis, L. A., & Milier, B. G. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00008 · Cited by 268
Compliance with antipsychotic drug treatment: influence of side effects
WW, F., U, M., V, G., & M, K. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05859.x · Cited by 241
The clinical implications of weight gain in schizophrenia.
Kurzthaler, I., & Fleischhacker, W. W. (2001) · PubMed · Cited by 166
The Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. Y. (1999) · Neuropsychopharmacology · doi:10.1038/sj.npp.1395370 · Cited by 164
Neuroleptic-induced hyperprolactinemia
Dickson, R. A., & Glazer, W. M. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00159-5 · Cited by 161
Partial dopamine agonists in the treatment of psychosis
Tamminga, C. A. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200033 · Cited by 150
Lahti, A. C., Weiler, M. A., Corey, P. K., Lahti, R. A., Carlsson, A., & Tamminga, C. A. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00030-9 · Cited by 104
Inoue, T., Domae, M., Yamada, K., & Furukawa, T. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12799-7 · Cited by 92
Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’?
Roth, B. L., Sheffler, D. J., & Potkin, S. G. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00021-5 · Cited by 80
Self-citationRao, L., & Möller, H. (2008) · Neuropsychobiology · doi:10.1159/000119156 · Cited by 58
Gury, C., Canceil, O., & Iaria, P. (2000) · PubMed · Cited by 54
The Effect of the Partial Dopamine Agonist Terguride on Negative Symptoms in Schizophrenics
Olbrich, R., & Schanz, H. (1988) · Pharmacopsychiatry · doi:10.1055/s-2007-1017021 · Cited by 45
Olbrich, R., & Schanz, H. (1991) · Journal of Neural Transmission · doi:10.1007/bf01244973 · Cited by 28
Aripiprazole: A dopamine-serotonin system stabilizer
Kurahashi, N., McQuade, R. D., Burris, K. D., Jordan, S., Tottori, K., & Kikuchi, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)80255-4 · Cited by 25
Cited by
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003
Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., Goldberg, R., Green-Paden, L. D., Tenhula, W. N., Boerescu, D., Tek, C., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007071 · Cited by 757
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Metadata
- Authors
- Potkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M., Stock, E., Stringfellow, J., Ingenito, G., & Marder, S. R.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2003-07-01
- Volume
- 60
- Issue
- 7
- Pages
- 681
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2114801996
- Cited by
- 591
- References
- 33
- FWCI
- 28.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.